Full-Time

Information Management Specialist

Document Systems

Deadline 8/31/26
Merck

Merck

10,001+ employees

Pharmaceutical company developing medicines and vaccines

Compensation Overview

$96.2k - $151.4k/yr

+ Annual Bonus + Long-Term Incentive

No H1B Sponsorship

North Wales, PA, USA

Hybrid

Hybrid work arrangement; on-site requirements at West Point, PA.

Bachelor's, Master's

Category
Biology & Biotech (1)
Required Skills
LLM
Word/Pages/Docs
REST APIs
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides

Get referred to Merck

See people who can refer or advise you

Requirements
  • BS/BA degree including degrees in biological, chemical, computer science, and/or medical science disciplines - A minimum 3 years direct and relevant experience (OR) MS/MA, including degrees in biological, chemical, computer science, and/or medical science disciplines - A minimum 2 years direct and relevant experience.
  • Experience supporting nonclinical drug development programs within the pharmaceutical, biotechnology, or related industry
  • Direct, advanced experience with Veeva Vault operations and functions (e.g. super / advanced user, system owner, or equivalent); experience including process design / development, generation of procedural controls, and/or end-user support
  • Strong understanding of document lifecycle management, metadata, workflows, version control, and records management principles
  • Some experience with report automation functions and technology (e.g. API calls, data, prompt engineering, strong LLM usage, systems thinking, technical design, development, operation, implementation, business integration, etc.)
  • Experience with standard document publishing tools
  • Proven ability to review, revise, and prepare high-quality documents with accuracy and consistency
  • Excellent leadership skills, written and verbal communication skills (including a strong command of English grammar, editing, and proofreading)
  • Proficient in Microsoft Office Suite (Word, Excel, PowerPoint, Outlook) and other business-related computer systems and software applications
  • Demonstrated exceptional attention to detail with a strong commitment to accuracy, quality, and compliance
Responsibilities
  • Actively contribute to report automation efforts by using advanced document management systems skills (e.g. APIs, data structures, and document / content knowledge). Bring strong process and systems thinking to bear to drive business integration and enable scalable solutions that facilitate the effective and compliant use of generative AI in document generation in PCD.
  • Collaborate with appropriate specialists to build, implement, and train users on related processes and tools for cross-functional participation. Utilize advanced document management skills (e.g. Veeva super user or equivalent skills) to troubleshoot and resolve issues and recommend process and functionality improvements. Contribute to the training and skills development of end-users.
  • Using document management, publishing, and project planning tools, manage the generation of nonclinical study and supporting documents from creation through to finalization through careful oversight of required processes, content development & review, and document integration.
  • Facilitate quality review to ensure that documents are appropriate, complete, and consistent with regulatory and company expectations.
  • Careful collaboration with internal and external stakeholders throughout the document development and related processes.
  • Participate in the development and implementation of tools and metrics to understand and improve processes and productivity.
Desired Qualifications
  • 2+ years of experience supporting document management systems, scientific platforms, enterprise content management, or regulated business applications
  • Experience with Python, prompt engineering, strong LLM usage a plus
  • Experience gathering business requirements and translating them into technology solutions
  • Solid understanding of applicable GxP regulations highly preferred

Merck is a global healthcare company that develops medicines, vaccines, and animal health products. It advances long-term health by conducting research and development to create new treatments for diseases such as cardiovascular disease, diabetes, and cancer, then brings these medicines to patients, healthcare professionals, and institutions worldwide. The company’s products work by undergoing scientific discovery, clinical testing, and regulatory approval before being manufactured and sold or distributed through patient assistance programs. What sets Merck apart is its large, diversified portfolio across human medicines, vaccines, and animal health, along with a strong emphasis on R&D, global reach, and support services like Merck Connect and Merck Manuals that provide professional resources. Merck’s goal is to tackle major health threats by applying science to discover and deliver therapies that improve patient outcomes and public health across the globe.

Company Size

10,001+

Company Stage

IPO

Headquarters

Kenilworth, Illinois

Founded

1891

Get referred to Merck

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue reached $16.6 billion, up 5% year over year.
  • INTerpath-001 met RFS and DMFS endpoints on August 19, 2026.
  • Merck will present data and pursue filings, expanding intismeran into more tumors.

What critics are saying

  • Keytruda patents start expiring in 2028, exposing Merck to biosimilar erosion.
  • Gardasil layoffs in North Carolina began May 2026, signaling demand weakness and cost pressure.
  • If intismeran disappoints beyond melanoma, Merck loses its clearest post-Keytruda replacement.

What makes Merck unique

  • Keytruda generated $8.37 billion in Q2 2026, powering Merck’s oncology scale.
  • Merck’s August 19, 2026 intismeran win validates individualized mRNA oncology manufacturing.
  • Merck split Human Health on February 23, 2026, sharpening oncology focus.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

-20%

1 year growth

-20%

2 year growth

-20%
Yahoo Finance
Aug 21st, 2026
Musk backs mRNA potential as Moderna and Merck trial shows cancer vaccine breakthrough

Elon Musk said mRNA technology has "tremendous promise for curing diseases" despite what he termed its "obvious misuse during Covid". The Tesla chief executive officer suggested artificial RNA essentially makes curing diseases a software problem. Musk's comments came as Moderna and Merck announced positive Phase 3 results for an individualised mRNA cancer vaccine. The treatment showed significant improvement in recurrence-free and metastasis-free survival in melanoma patients when combined with Merck's Keytruda. This marks the first successful late-stage trial of its kind. Musk has previously promoted artificial intelligence as a path to transforming healthcare. In June, he said advances in synthetic RNA could potentially "cure almost anything".

Yahoo Finance
Aug 20th, 2026
Merck takes $3.8M stake in AI vaccine developer Evaxion after licensing bacterial candidate

Merck & Company disclosed holding 1,214,126 shares of AI immunology firm Evaxion A/S in a regulatory filing on 10 August. Evaxion shares rose 2% to $3.17 following the announcement. The position follows Merck's September 2025 decision to in-license EVX-B3, Evaxion's discovery-stage vaccine candidate targeting an undisclosed bacterial pathogen. Argus raised its price target on Merck from $130 to $145 on 11 August, citing regulatory approvals and pipeline depth. Merck reported Q2 2026 revenue of $16.6 billion, up 5% year-over-year, driven by $8.4 billion from KEYTRUDA. Evaxion reported zero revenue in Q1 2026 with a net loss of $3.6 million. Hedge fund holdings in Merck fell from 100 funds in Q4 2025 to 98 in Q1 2026.

Yahoo Finance
Aug 20th, 2026
Merck dips 0.5% after 12.6% surge on positive cancer-vaccine trial results

Merck shares dipped approximately 0.5% to $151.39 on Thursday following a 12.6% surge the previous day, reaching a record close. The pharmaceutical company's stock jumped after positive results from a Phase 3 trial testing a personalized melanoma vaccine developed with Moderna. The 1,137-patient study met its primary endpoints for recurrence-free survival and distant-metastasis-free survival. The trial compared Keytruda alone against Keytruda plus intismeran in patients with surgically removed high-risk melanoma, with no new safety concerns identified. Merck and Moderna are also testing the vaccine platform in lung, bladder, kidney, pancreatic and stomach cancers. Keytruda generated approximately $8.4 billion in second-quarter sales, representing roughly half of Merck's revenue. The stock now trades 26.28% above its estimated fair value of $119.88.

Yahoo Finance
Aug 20th, 2026
Merck surges 12.6% as personalised cancer vaccine beats standard melanoma treatment

Merck announced its personalised cancer vaccine combined with immunotherapy Keytruda significantly improved outcomes for melanoma patients in a Phase 3 trial. The 135-year-old drugmaker's stock jumped 12.6% on 19 August following the news. The trial tested intismeran autogene, developed with Moderna, alongside Keytruda in patients with surgically removed stage IIB through IV melanoma. Patients receiving the combination stayed cancer-free longer and experienced delayed cancer spread compared to those on Keytruda alone. The treatment uses mRNA technology tailored to each patient's tumour mutations, training the immune system to target up to 34 specific genetic changes. It marks the first time an individualised cancer vaccine has shown positive results in late-stage testing. Keytruda generated $8.4 billion in second-quarter sales, representing over 50% of Merck's quarterly revenue.

Yahoo Finance
Aug 20th, 2026
Merck melanoma vaccine trial beats expectations, but RBC downgrades stock over $30B Keytruda patent cliff

Merck's promising Phase 3 melanoma trial results drew mixed reactions from Wall Street. RBC Capital downgraded Merck to 'Sector Perform' from 'Outperform', calling the stock's $150 valuation "unprecedented" for a company facing major patent expiry in two years. Key patents covering Keytruda, Merck's best-selling cancer drug that generated over $30 billion in 2025 and represents nearly half of its revenue, begin expiring in 2028. RBC said further gains would require the pipeline to exceed already elevated expectations. However, BofA maintained its 'Buy' rating, raising its price target to $166, citing confidence that Merck can offset Keytruda's patent challenges. BMO Capital raised its target to $170, noting the trial could represent $5.6 billion in potential peak revenue. The trial tested Intismeran Autogene with Keytruda in melanoma patients, significantly extending time without recurrence.